Data di Pubblicazione:
2019
Citazione:
Impact of HCV and Direct Acting Antivirals on Kidney Recipients: a retrospective study / M. Gendia, P. Lampertico, C.M. Alfieri, R. D'Ambrosio, M.T. Gandolfo, M.R. Campise, F. Fabrizi, P. Messa. - In: TRANSPLANT INTERNATIONAL. - ISSN 0934-0874. - 32:5(2019 May), pp. 493-501. [10.1111/tri.13393]
Abstract:
Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5%) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30%) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Hepatitis-C; direct acting antivirals; graft outcome; kidney transplantation
Elenco autori:
M. Gendia, P. Lampertico, C.M. Alfieri, R. D'Ambrosio, M.T. Gandolfo, M.R. Campise, F. Fabrizi, P. Messa
Link alla scheda completa: